Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p38γ RNAi
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
p38γ RNAi refers to RNA interference (RNAi) agents, such as small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), designed to selectively silence the expression of p38γ (mitogen-activated protein kinase 12, or MAPK12). p38γ is an isoform of the p38 mitogen-activated protein kinase (MAPK) family. In research settings, particularly in oncology, p38γ RNAi is utilized to investigate the role of p38γ in cancer progression, cell motility, invasion, and metastasis. Knockdown of p38γ in aggressive breast cancer cell lines has been shown to impair cell motility and metastasis, suggesting its potential as a therapeutic target. Currently, p38γ RNAi is primarily employed as a laboratory research tool rather than an approved clinical therapeutic.
- Other names
- MAPK12 RNAiMAPK-12 RNAiMAPK 12 RNAiMAPK12 siRNAMAPK-12 siRNAMAPK 12 siRNAp38 gamma RNAip-38 gamma RNAip 38 gamma RNAip38 gamma siRNAp-38 gamma siRNAp 38 gamma siRNAp38γ siRNA
02
Targets
RHOC (Ras homolog family member C)MAPK12 (Mitogen-activated protein kinase 12)
Beyond the preview
Go deeper on p38γ RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p38γ RNAi.